Pulse Biosciences Chief Commercial Officer Kevin Patrick Danahy sold 60,000 shares of company stock for a total of $1.41 million between February 12 and 17, 2026. These sales were executed under a Rule 10b5-1 trading plan. This comes as Pulse Biosciences continues to make significant advancements in its clinical trials for the nPulse Cardiac Catheter System and the nPulse Vybrance Percutaneous Electrode System, garnering positive analyst coverage.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Pulse Biosciences CCO Danahy sells $1.41 million in stock By Investing.com
Pulse Biosciences Chief Commercial Officer Kevin Patrick Danahy sold 60,000 shares of company stock for a total of $1.41 million between February 12 and 17, 2026. These sales were executed under a Rule 10b5-1 trading plan. This comes as Pulse Biosciences continues to make significant advancements in its clinical trials for the nPulse Cardiac Catheter System and the nPulse Vybrance Percutaneous Electrode System, garnering positive analyst coverage.